Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia

New England Journal of Medicine

Volumn 344, Issue 7, 2001, Pages 472-480

  Deeks, Steven G ^a,b   Wrin, Terri ^c   Liegler, Teri ^d   Hoh, Rebecca ^a,b   Hayden, Matthew ^d   Barbour, Jason D ^d   Hellmann, Nicholas S ^c   Petropoulos, Christos J ^c   McCune, Joseph M ^d   Hellerstein, Marc K ^e   Grant, Robert M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS CULTURE; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RNA, VIRAL; VIREMIA;

EID: 0035864943     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200102153440702     Document Type: Article

References (14)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
4. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
5. Highly active antiretrovial therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
6. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
7. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
8. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
9. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
10. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
11. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
12. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
13. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
14. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy